AbbVie Inc. $ABBV Stock Holdings Reduced by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its position in AbbVie Inc. (NYSE:ABBV) by 1.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,362,464 shares of the company’s stock after selling 19,132 shares during the quarter. AbbVie makes up about 1.0% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 14th largest holding. Handelsbanken Fonder AB’s holdings in AbbVie were worth $342,850,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Ranch Capital Advisors Inc. boosted its position in AbbVie by 37.0% during the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after purchasing an additional 4,017 shares during the period. Calamos Advisors LLC raised its position in shares of AbbVie by 3.4% in the fourth quarter. Calamos Advisors LLC now owns 466,290 shares of the company’s stock valued at $106,543,000 after purchasing an additional 15,458 shares during the period. Bingham Private Wealth LLC acquired a new stake in shares of AbbVie in the fourth quarter worth $1,147,000. Axecap Investments LLC lifted its stake in shares of AbbVie by 713.2% in the fourth quarter. Axecap Investments LLC now owns 16,320 shares of the company’s stock worth $3,729,000 after buying an additional 14,313 shares during the last quarter. Finally, Legacy Edge Advisors LLC bought a new stake in shares of AbbVie during the 4th quarter worth $1,265,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
• Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
• Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
• Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
• Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.

Analysts Set New Price Targets

ABBV has been the subject of a number of research analyst reports. JPMorgan Chase & Co. boosted their target price on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Cantor Fitzgerald lifted their price objective on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Morgan Stanley reissued an “overweight” rating and set a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Finally, Wells Fargo & Company increased their target price on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.70.

AbbVie Price Performance

Shares of ABBV stock opened at $247.86 on Tuesday. AbbVie Inc. has a one year low of $190.75 and a one year high of $267.47. The stock has a fifty day moving average price of $242.67 and a 200 day moving average price of $225.28. The stock has a market cap of $437.92 billion, a P/E ratio of 70.02, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio is 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.